• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters1
Displaying 144-145 of 145 results

1015 Exhibit: Cartt et al, US Patent Application Publication No US 20080279784, Nasal Administration Of Benzodiazepines, Serial No 12116,842, published November 13, 2008 Cartt ¿¿¿784

Document IPR2019-00450, No. 1015 Exhibit - Cartt et al, US Patent Application Publication No US 20080279784, Nasal Administration Of Benzodiazepines, Serial No 12116,842, published November 13, 2...
In some embodiments, the nanoparticulate benZodiaZepine particles comprise at least one member of the group consisting of alpraZolam, brotiZolam, chlordiaZepoxide, clobaZam, clon aZepam, cloraZepam, demoxaZepam, ?umaZenil, ?uraZepam, halaZepam, midaZolam, nordaZepam, medaZepam, diaZ AQUESTIVE EXHIBIT 1015 page 0006
In some embodiments, the nanoparticulate benZodi aZepine particles comprise at least one member of the group consisting of alpraZolam, diaZepam, ?uraZepam, loraZepam, medaZepam, mexaZolam, midaZolam, temaZepam and phar maceutically acceptable salts and combinations thereof.
In some embodiments, the benZodiaZepine particles comprise at least one member of the group consist ing of alpraZolam, diaZepam, ?uraZepam, loraZepam, medaZepam, mexaZolam, midaZolam, temaZepam and phar maceutically acceptable salts and combinations thereof.
In some embodiments, the nanoparticulate benZodiaZepine particles comprise at least one member of the group consisting of alpraZolam, diaZepam, ?uraZepam, loraZepam, medaZepam, mexaZolam, mida Zolam, temaZepam and pharmaceutically acceptable salts and combinations thereof.
In some embodiments, the nanoparticulate benZodiaZepine particles comprise at least one member of the group consisting of alpraZolam, diaZepam, ?uraZepam, loraZepam, medaZepam, mexaZolam, mida Zolam, temaZepam and pharmaceutically acceptable salts and combinations thereof.
cite Cite Document
Analyze

1040 Exhibit: Part 2 Pages 251 500 File History for EP 128 013729, based on WO 2012174158 and PCTUS2012042311

Document IPR2019-00450, No. 1040-2 Exhibit - Part 2 Pages 251 500 File History for EP 128 013729, based on WO 2012174158 and PCTUS2012042311 (P.T.A.B. Jan. 29, 2019)
... citations and explanations supporting such statement Statement Novelty (N) Inventive step (1S) Industrial applicability (IA) Claims Claims 9-12, 32-35 1-8, 13-31, 36-62 Claims Claims Claims Claims NONE 1-62 1-62 NONE ...
Nonetheless, social objections by older children and adults and legal concerns about rectal adminis- tration havelimited its use.
... (hours) Figure 2 Mean (+standard deviation) plasma concentration—timeprofiles of diazepam after intravenous and intranasal adminis- tration in twenty-four subjects (semi-logarithmic scale). criteria of a serious adverse event, and none ...
Noneof the cited documents discloses a pharmaceutical solution having a composition as definedin claim 1 for nasal administration for treating seizures.
Noneofthe cited prior art documents teaches that an improved treatment of seizures can be achieved when using a combination of ethanol and benzy! alcoholin a nasal pharmaceutical solution comprising a benzodiazepine drug.
... 0322 page 0322 TA eeeName: Galvez, Joélle European Patent Office Postbus 5818 2280 HV Rijswijk NETHERLANDS Tel: +31 70 340 2040 Fax: +31 70 340 3016 Tel: +31 70 340 - 2434 or call +31 (0)70 340 45 00 . . NoneGamerGalarde, ...
Indeed, consistent with Sonne’s general teaching at column 3, lines 65-67, none of the Examples taught by Sonne suggest nasal administration of a benzodiazepine drug formulation that contains only tocopherol or tocotrienol, an ...
None of the six volunteers had local irritation of the nostrils 30 minutes after application, see table 2.
cite Cite Document
Analyze
+ More Snippets
<< 1 2 3 4 5 ... 9 10 11

Can’t find a case you think should be here?

Use our supplemental search tool to find dockets that you may not see here. Information on Fees

Start a Supplemental Search